New insight of metabolomics in ocular diseases in the context of 3P medicine

EPMA J. 2023 Feb 17;14(1):53-71. doi: 10.1007/s13167-023-00313-9. eCollection 2023 Mar.

Abstract

Metabolomics refers to the high-through untargeted or targeted screening of metabolites in biofluids, cells, and tissues. Metabolome reflects the functional states of cells and organs of an individual, influenced by genes, RNA, proteins, and environment. Metabolomic analyses help to understand the interaction between metabolism and phenotype and reveal biomarkers for diseases. Advanced ocular diseases can lead to vision loss and blindness, reducing patients' quality of life and aggravating socio-economic burden. Contextually, the transition from reactive medicine to the predictive, preventive, and personalized (PPPM / 3P) medicine is needed. Clinicians and researchers dedicate a lot of efforts to explore effective ways for disease prevention, biomarkers for disease prediction, and personalized treatments, by taking advantages of metabolomics. In this way, metabolomics has great clinical utility in the primary and secondary care. In this review, we summarized much progress achieved by applying metabolomics to ocular diseases and pointed out potential biomarkers and metabolic pathways involved to promote 3P medicine approach in healthcare.

Keywords: Age-related macular degeneration; Biomarkers; Diabetic retinopathy; Glaucoma; Metabolomics; Ocular diseases; Predictive preventive personalized medicine (3PM / PPPM).

Publication types

  • Review